1 defensive stock I’d buy alongside FTSE 100 peer Shire plc

The sell-off in defensive stocks is throwing up opportunities like Shire (LON SHP) and this share.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Analysts at Societe Generale went on record this week to say that the current valuation of defensive pharmaceutical operator Shire (LSE: SHP) “makes no sense.” They think the firm is selling too cheap and that we should buy the company’s shares.

The company seems to have fallen out of favour with investors as it digests its 2016 gargantuan acquisition of Baxalta, and the higher debt-load the firm took on seems to be giving investors indigestion when it comes to the shares. But I think something worth holding will emerge from the story and the value is becoming compelling. Growth could follow and the shares will likely turn back up. That’s why I was eagerly awaiting the full-year figures that hit the newswires this morning.

A compelling update

The update is encouraging. Underlying revenue is 32% higher than the previous year, underlying diluted earnings per share pushed up 16% and net cash from operations surged 60% higher. The directors demonstrated their optimism by pushing up the total dividend for 2017 by 15%.

Looking forward, Chief executive Flemming  Ornskov thinks the mid-term outlook is positive for growth because of the firm’s immunology franchise, multiple near-term launches, and participation in international markets. He says Shire aims to achieve a revenue target of $17bn to $18bn in 2020. However, during 2018, he expects underlying diluted earnings growth to come in below the rate of revenue growth during 2018, “mainly due to costs incurred from the start-up of our new US plasma manufacturing site, intensifying genericization, and lower royalties.”

A market-wide sell-off of defensive stocks

In addition to the big acquisition muddying the water, I think Shire might have been caught up the wider the sell-off of defensive shares we’ve seen over the past year or so. Today’s share price around 3,141p means you can pick up the stock on a forward price-to-earnings (P/E) rating for 2018 of just eight. I’m tempted to do just that and would consider the firm alongside fellow defensive play Pennon Group (LSE: PNN), the water and waste utility provider.

Pennon’s share price has been slipping, down 29% since June. The firm endured several years of falling earnings but that slide looks set to stop during the current year. In November, the firm reported half-year results showing revenue 5.6% higher than the year before and earnings per share up 7.2%. The directors marked the occasion by pushing up the interim dividend 7.9%.

Earnings look set to turn a corner after the company’s relentless focus on cost control and continuing investment in efficiency improvements. City analysts following the firm expect earnings to lift 13% for the trading year to March 2019 and 10% the year after that. Maybe the wider sell-off of defensive shares is affecting the share-price trend at the very point that Pennon is turning itself around. If so, I think the intersection of a rising growth trend and a falling share price is throwing up an opportunity for investors. At today’s share price around 627p, the forward P/E rating for next year is just below 12 and the forward dividend yield sits at 6.6%. I think that valuation is attractive.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended Pennon Group and Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »

Investing Articles

Down 78%, is this once-hot AI growth stock set to explode like the Rolls-Royce share price?

Our writer asks if he should invest in Super Micro Computer (NASDAQ:SMCI) following the growth stock's massive recent decline.

Read more »

Investing Articles

Is it madness to buy Palantir shares after Q3 earnings?

Palantir stock's surging again after the firm's Q3 earnings report. But after a 150% gain, is it too late to…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£6,000 in savings? Here’s how I’d aim to turn that into £1,032 a month of passive income!

A small investment in high-dividend-paying stocks with the returns used to buy more shares can generate big passive income over…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

As Lloyds’ share price tumbles 14%, is this an unmissable opportunity for me to buy at a bargain-basement price?

The Lloyds share price is substantially below its year high, but decent earnings prospects should drive its price and dividend…

Read more »